Literature DB >> 29995452

Development and Characterization of Quantitative, High-Throughput-Compatible Assays for Proteolytic Degradation of Glucagon.

Caitlin N Suire1, Shelley Lane1, Malcolm A Leissring1.   

Abstract

Glucagon is a vital peptide hormone involved in the regulation of blood sugar under fasting conditions. Although the processes underlying glucagon production and secretion are well understood, far less is known about its degradation, which could conceivably be manipulated pharmacologically for therapeutic benefit. We describe here the development of novel assays for glucagon degradation, based on fluoresceinated and biotinylated glucagon (FBG) labeled at the N- and C-termini, respectively. Proteolysis at any peptide bond within FBG separates the fluorescent label from the biotin tag, which can be quantified in multiple ways. In one method requiring no specialized equipment, intact FBG is separated from the cleaved fluoresceinated fragments using NeutrAvidin agarose beads, and hydrolysis is quantified by fluorescence. In an alternative, high-throughput-compatible method, the degree of hydrolysis is quantified using fluorescence polarization after addition of unmodified avidin. Using a known glucagon protease, we confirm that FBG is cleaved at similar sites as unmodified glucagon and use both methods to quantify the kinetic parameters of FBG degradation. We show further that the fluorescence polarization-based assay performs exceptionally well ( Z'-factor values >0.80) in a high-throughput, mix-and-measure format.

Entities:  

Keywords:  enzyme assays; enzyme kinetics; fluorescence methods; metabolic diseases; protease; ultra-high-throughput screening

Mesh:

Substances:

Year:  2018        PMID: 29995452      PMCID: PMC6585941          DOI: 10.1177/2472555218786509

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  28 in total

1.  Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.

Authors:  Samer O Abdul-Hay; Amy L Lane; Thomas R Caulfield; Clémence Claussin; Juliette Bertrand; Amandine Masson; Shakeel Choudhry; Abdul H Fauq; Guhlam M Maharvi; Malcolm A Leissring
Journal:  J Med Chem       Date:  2013-03-15       Impact factor: 7.446

Review 2.  The New Biology and Pharmacology of Glucagon.

Authors:  T D Müller; B Finan; C Clemmensen; R D DiMarchi; M H Tschöp
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

3.  Bacitracin: an inhibitor of the insulin degrading activity of glutathione-insulin transhydrogenase.

Authors:  R A Roth
Journal:  Biochem Biophys Res Commun       Date:  1981-01-30       Impact factor: 3.575

4.  Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.

Authors:  Wesley Farris; Malcolm A Leissring; Matthew L Hemming; Alice Y Chang; Dennis J Selkoe
Journal:  Biochemistry       Date:  2005-05-03       Impact factor: 3.162

5.  ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety.

Authors:  Eun Suk Song; Maria Aparecida Juliano; Luiz Juliano; Michael G Fried; Steven L Wagner; Louis B Hersh
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

6.  Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays.

Authors:  Malcolm A Leissring; Alice Lu; Margaret M Condron; David B Teplow; Ross L Stein; Wesley Farris; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

7.  Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.

Authors:  Ramona Trebbien; Letty Klarskov; Mette Olesen; Jens J Holst; Richard D Carr; Carolyn F Deacon
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-05-04       Impact factor: 4.310

8.  An AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production.

Authors:  Matthew R Evans; Shuguang Wei; Bruce A Posner; Roger H Unger; Michael G Roth
Journal:  J Biomol Screen       Date:  2015-12-16

9.  Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display.

Authors:  Caitlin N Suire; Sarah Nainar; Michael Fazio; Adam G Kreutzer; Tara Paymozd-Yazdi; Caitlyn L Topper; Caroline R Thompson; Malcolm A Leissring
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

10.  Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.

Authors:  Anthony Delledonne; Naomi Kouri; Lael Reinstatler; Tomoko Sahara; Lilin Li; Ji Zhao; Dennis W Dickson; Nilufer Ertekin-Taner; Malcolm A Leissring
Journal:  Mol Neurodegener       Date:  2009-10-16       Impact factor: 14.195

View more
  6 in total

1.  Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation.

Authors:  Beatriz Merino; Elena Casanueva-Álvarez; Iván Quesada; Carlos M González-Casimiro; Cristina M Fernández-Díaz; Tamara Postigo-Casado; Malcolm A Leissring; Klaus H Kaestner; Germán Perdomo; Irene Cózar-Castellano
Journal:  Diabetologia       Date:  2022-06-02       Impact factor: 10.460

Review 2.  Targeting Insulin-Degrading Enzyme in Insulin Clearance.

Authors:  Malcolm A Leissring; Carlos M González-Casimiro; Beatriz Merino; Caitlin N Suire; Germán Perdomo
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

Review 3.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17

4.  Quantitative, High-Throughput Assays for Proteolytic Degradation of Amylin.

Authors:  Caitlin N Suire; Monica K Brizuela; Malcolm A Leissring
Journal:  Methods Protoc       Date:  2020-11-24

5.  Insulin-Degrading Enzyme: Paradoxes and Possibilities.

Authors:  Malcolm A Leissring
Journal:  Cells       Date:  2021-09-16       Impact factor: 6.600

6.  Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.

Authors:  Rebecca N Adamek; Caitlin N Suire; Ryjul W Stokes; Monica K Brizuela; Seth M Cohen; Malcolm A Leissring
Journal:  ChemMedChem       Date:  2021-03-31       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.